A Phase 1 Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human open-label Phase 1 study to evaluate the safety, tolerability,
pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by
intravenous infusion in patients with advanced solid malignancies who have progressed on all
available standard therapies